Windlas Biotech Limited concludes SAHPRA Audit

Windlas Biotech Limited, one of the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization ("CDMO") industry in India, has concluded SAHPRA (South African Health Products Regulatory Authority) inspection audit report for the Plant-IV situated at Dehradun with zero critical observations / deficiencies, zero major deficiencies and some minor deficiencies. The company had undergone the inspection audit from 20th to 29th September 2021.

Commenting on this Mr. Hitesh Windlass, Managing Director - Windlas Biotech said, "We are very happy to receive zero critical observations and deficiencies. The successful completion of the audit will enable us to open up new geography and strengthen our presence in South Africa."

Shares of Windlas Biotech Ltd was last trading in BSE at Rs. 261.25 as compared to the previous close of Rs. 260.60. The total number of shares traded during the day was 5012 in over 417 trades.

The stock hit an intraday high of Rs. 264.90 and intraday low of 259.00. The net turnover during the day was Rs. 1308749.00.

Source : Equity Bulls

Keywords

WindlasBiotech SAHPRA Inspection Dehradun